Sai Life Sciences Limited has scheduled meetings with analysts and investors in Mumbai for June 3 and June 4, 2026, as part of its engagement with the financial community. The company will participate in the Morgan Stanley India Investment Forum 2026 and the Citi India Conference 2026 during this period. These interactions provide a platform for the company to present its operational strategy and performance to potential investors.

The meetings are being conducted in accordance with Regulations 30 read with Schedule III of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015. Runa Karan, Company Secretary & Compliance Officer, confirmed the schedule in a filing submitted to the stock exchanges on May 27, 2026.

The company clarified that it does not intend to discuss any unpublished price sensitive information during the meetings. Additionally, no new presentation is scheduled to be released for these events. The schedule remains subject to changes based on exigencies on the part of the analysts, investors, or the company.

Sai Life Sciences has filed the transcript of its earnings call for the audited financial results for the quarter and year ended March 31, 2026. The call was held on Friday, May 15, 2026, at 04:00 PM (IST) pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015. The transcript has been uploaded to the company's website.

The company previously announced its audited financial results for FY26, reporting a 29% year-on-year increase in revenue to ₹2,192 crore. Profitability metrics improved significantly, with Profit After Tax (PAT) rising 109% to ₹355 crore from ₹170 crore in FY25. For Q4FY26, revenue from operations stood at ₹602 crore, a 4% year-on-year increase, while PAT for the quarter grew 18% to ₹104 crore.

Financial Performance

The company delivered robust operational efficiency across both the quarter and the full year. EBITDA for FY26 grew 56% to ₹661 crore, with the EBITDA margin expanding to 30% from 25% in the prior year. PAT margin improved to 16% from 10% in FY25. At the quarterly level, Q4FY26 EBITDA rose 17% to ₹189 crore, with an EBITDA margin of 31% compared to 28% in Q4FY25. The company also incurred a capital expenditure (capex) of ₹633 crore during FY26.

The following table presents the key financial metrics for the quarter and full year:

*before exceptional items

Five-Year KPI Trend

The investor presentation highlighted a consistent multi-year growth trajectory across key financial and return metrics. The following table summarises the five-year KPI trend from FY22 to FY26:

Management Commentary

Commenting on the performance, Mr. Krishna Kanumuri, Managing Director and CEO, said, "FY26 was an important year for Sai Life Sciences as we continued to deepen our relationships with global pharma customers, expand our integrated CRDMO capabilities, and invest for the next phase of growth. While the operating environment remains dynamic, we believe the long-term fundamentals of innovation-led outsourcing and supply chain diversification continue to remain strong, and we are well positioned to participate meaningfully in this opportunity."

Mr. Siva Chittor, Chief Financial Officer, added, "FY26 reflected strong execution across the business, supported by healthy growth in both revenues and EBITDA. As we enter the next phase of expansion, we remain focused on disciplined capital allocation, operational resilience, and investments that are closely aligned with customer demand and long-term strategic opportunities."

Business Updates

The investor presentation highlighted deepening engagement with global large pharma customers across Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) segments. Dedicated R&D team models gained strong traction, with relationships expanding from early discovery to commercial manufacturing. The company received commercial supply qualification from two additional large pharma customers. Integrated CRO strategy with biotech and pharma customers continued to scale, with growing cross-sell opportunities with existing CDMO customers and increased traction for larger and more customized discovery programs.

On the technology front, the company established a High-Throughput Experimentation (HTE) platform at its Hyderabad R&D campus and is expanding capabilities in Peptides and Antibody-Drug Conjugates (ADCs). Sai Life Sciences is also advancing digital and AI-led productivity initiatives across scientific operations, focused on improving speed, efficiency, and problem-solving capabilities. On the sustainability front, the company's Bidar manufacturing sites (Unit IV and Unit VI) have become the first sites of an Indian CRDMO to operate on 100% renewable power.

Earnings Call

Sai Life Sciences conducted its earnings call on May 15, 2026, to discuss the financial and business performance of the quarter and full year. Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, the recording of the earnings call is now available on the company's website. Key details of the call are as follows: